Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $26.72 USD
Change Today -0.96 / -3.47%
Volume 193.6K
CHRS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 4:00 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

coherus biosciences inc (CHRS) Snapshot

Open
$27.70
Previous Close
$27.68
Day High
$27.99
Day Low
$26.55
52 Week High
07/22/15 - $38.10
52 Week Low
11/6/14 - $12.27
Market Cap
1.0B
Average Volume 10 Days
198.7K
EPS TTM
$-7.15
Shares Outstanding
38.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for COHERUS BIOSCIENCES INC (CHRS)

Related News

No related news articles were found.

coherus biosciences inc (CHRS) Related Businessweek News

No Related Businessweek News Found

coherus biosciences inc (CHRS) Details

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

95 Employees
Last Reported Date: 08/10/15
Founded in 2010

coherus biosciences inc (CHRS) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $450.2K
Chief Financial Officer
Total Annual Compensation: $102.4K
Chief Medical Officer
Total Annual Compensation: $443.0K
Chief Scientific Officer
Total Annual Compensation: $352.2K
Compensation as of Fiscal Year 2014.

coherus biosciences inc (CHRS) Key Developments

Coherus Biosciences, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Coherus Biosciences, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. Total revenue for the second quarter 2015 was $6.9 million, as compared to $5.0 million in the second quarter of 2014. The higher revenue in the second quarter and first half of 2015 over the same periods in 2014 was due to the recognition of increased Baxalta collaboration revenue as a result of milestone payments received and amortized over the past 12 months. Net loss attributable to Coherus for the second quarter 2015 was $58.8 million, or $1.56 per share, compared to $25.0 million, or $5.96 per share, for the same period in 2014. Loss from operations was $58.89 million against $17.93 million a year ago. Total revenue for the six months ended June 30, 2015 was $12.7 million, as compared to $8.6 million for the same period in 2014. Net loss attributable to Coherus for the second quarter 2015 was $99.87 million, or $2.80 per share, compared to $50.24 million, or $11.99 per share, for the same period in 2014. Loss from operations was $95.64 million against $31.69 million a year ago.

Coherus Biosciences, Inc. to Report Q2, 2015 Results on Aug 10, 2015

Coherus Biosciences, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 10, 2015

Coherus Biosciences, Inc., Q2 2015 Earnings Call, Aug 10, 2015

Coherus Biosciences, Inc., Q2 2015 Earnings Call, Aug 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CHRS:US $26.72 USD -0.96

CHRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CHRS.
View Industry Companies
 

Industry Analysis

CHRS

Industry Average

Valuation CHRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.6x
Price/Book 10.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COHERUS BIOSCIENCES INC, please visit www.coherus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.